Platelet Activating Factor Acetylhydrolase (PAF-AH)

Specification

• Cat#: THP-0249
• Product Name: Platelet Activating Factor Acetylhydrolase (PAF-AH)
• Description: Recombinant Human PAF-AH is a 420 amino acid glycoprotein which migrates with an apparent molecular mass of 47-55 kDa by SDS-PAGE analysis. Recombinan Human PAF-AH has a calculated, theoretical molecular weight of 47.8 kDa.
• Sequences: FDWQYINPVA HMKSSAWVNK IQVLMAAASF GQTKIPRGNG PYSVGCTDLM FDHTNKGTFL RLYYPSQDND RLDTLWIPNK EYFWGLSKFL GTHWLMGNIL RLLFGSMTTP ANWNSPLRPG EKYPLVVFSH GLGAFRTLYS AIGIDLASHG FIVAAVEHRD RSASATYYFK DQSAAEIGDK SWLYLRTLKQ EEETHIRNEQ VRQRAKECSQ ALSLILDIDH GKPVKNALDL KFDMEQLKDS IDREKIAVIG HSFGGATVIQ TLSEDQRFRC GIALDAWMFP LGDEVYSRIP QPLFFINSEY FQYPANIIKM KKCYSPDKER KMITIRGSVH QNFADFTFAT GKIIGHMLKL KGDIDSNVAI DLSNKASLAF LQKHLGLHKD FDQWDCLIEG DDENLIPGTN INTTNQHIML QNSSGIEKYN
• Species: Human
• Molecular Weight: 47.8 kDa
• Source: HEK293 cells
• Introduction: Platelet Activating Factor (PAF) is a biologically active phospholipid, which exerts primarily proinflammatory activities by specifically signaling through G-protein-coupled receptors on platelets, neutrophils, and monocytes. Platelet Activating Factor Acetylhydrolase (PAF-AH) is a secreted protein that mediates PAF activity by specifically catalyzing hydrolysis of the “sn2” ester bond, resulting in the conversion of PAF to the biologically inactive lyso-PAF. PAF-AH can also interact with LDL particles to induce the hydrolysis of LDL-associated, oxidized phospholipids, generating lysophosphatidylcholine (lyso-PC) and other lysophospholipids.
• Purity: ≥95% by SDS-PAGE gel and HPLC analyses.
• Biological Activity: Measured by its ability to cleave a PAF analog in a chromogenic substrate linked assay. At a PAF-AH concentration of 10.0 μg/ml, 50% cleavage was achieved at an incubation time of approximately 2 minutes.
• Application: Platelet Activating Factor Acetylhydrolase (PAF-AH) is a secreted protein that mediates PAF activity by specifically catalyzing hydrolysis of the “sn2” ester bond, resulting in the conversion of PAF to the biologically inactive lyso-PAF.

Related Reading

Background of PAF-AH

PAF-AH (Platelet activating factor acetylhydrolase) is an esterase that can catalyze the hydrolysis of phosphatidylcholine acyl groups, initially isolated from platelets.

The discovery history of PAF-AH began in the 1980s. At that time, researchers discovered an esterase on platelets that could hydrolyze phosphatidylcholine and named it PAF-AH. Soon, this esterase was also found to exist in other cells, such as white blood cells and liver cells. Later, scientists discovered that PAF-AH was associated with some diseases, such as cardiovascular disease and inflammatory disease, and therefore conducted more in-depth research on it.

The gene encoding site of PAF-AH is located in the human chromosome 6p21.3 region, containing 9 exons and 8 introns. The secondary structure of PAF-AH protein consists of the N-terminus α- Spiral zone, central β- Folding area and C-end α- The spiral zone is composed of a "horseshoe shaped" structure as a whole.

Function of PAF-AH

PAF-AH protein has important functions, including catalyzing the hydrolysis of PAF, anti-inflammatory, antioxidant, and anti-platelet aggregation. PAF is an important molecule that promotes physiological functions such as platelet aggregation, vasodilation, and inflammatory response. It is normally synthesized by PAF acyltransferase and can be produced by various immune cells during inflammation and infection, leading to inflammatory reactions. The function of PAF-AH is to hydrolyze PAF into inactive molecules, thereby regulating inflammatory response and platelet aggregation function.

PAF-AH related signal pathway

The signal pathway of PAF-AH is relatively complex. Research has shown that PAF-AH exerts its biological effects through multiple pathways. For example, PAF-AH can be combined with important immune response pathways such as TLR2/4, NF- κB pathway, inducing inflammatory responses, mediating autophagy, and regulating cell apoptosis. In addition, PAF-AH is also associated with the antioxidant pathway, exerting antioxidant and anti-inflammatory effects.

PAF-AH related diseases

PAF-AH is associated with various diseases, such as cardiovascular disease, stroke, asthma, inflammatory diseases, etc. Research shows that PAF-AH can regulate thrombosis, control vascular permeability, and inhibit inflammatory reaction and other effects, thus affecting the occurrence and development of cardiovascular diseases. In some autoimmune diseases (such as rheumatoid arthritis and lupus erythematosus), abnormal expression of PAF-AH can lead to uncontrolled immune response and exacerbate disease progression.

The application of PAF-AH in medicine

PAF-AH has potential application value in medicine. For example, using PAF-AH as a target for treating cardiovascular diseases can lead to the development of new drugs. In addition, PAF-AH also has certain application prospects in new drug screening and clinical diagnosis.

Currently, many PAF-AH related drugs are being developed. The most representative is darapradib, which is an oral drug that has entered the clinical trial stage. Darapradib can selectively inhibit the activity of PAF-AH, thereby reducing inflammatory response and the progression of cardiovascular disease. In addition, there is research on the basic proteins and genes of PAF-AH, exploring its biological functions, such as molecular diagnosis, anti-inflammatory, and antioxidant applications. These research findings provide new ideas for the development of new drugs and the treatment of diseases.